US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

TRAWS PHARMA

1.65

+0.170011.49%

Post-market: 1.670.0200+1.21%19:59 EDT

Volume:493.13K

Turnover:807.06K

Market Cap:9.18M

PE:-0.05

High:1.73

Open:1.46

Low:1.45

Close:1.48

Loading ...

Overview Company News Filings

BRIEF-Traws Pharma Announces Receipt Of FDA Guidance On Tivoxavir Marboxil, Plans For Pursuing Stockpiling For Pandemic Preparedness

Traws Pharma Announces Receipt of FDA Guidance on Tivoxavir Marboxil and Reports Plans for Pursuing Stockpiling for Pandemic Preparedness

THOMSON REUTERS

BRIEF-Traws Pharma Reports First Quarter 2025 Results And Business Highlights

Traws Pharma Q1 EPS $2.09 Beats $(8.04) Estimate, Sales $57.00K Miss $60.00K Estimate

Traws Pharma Inc. Reports Q1 2025 Results: Revenue Steady at $57K, Net Income Soars to $21.5M, EPS at $2.17

Traws Pharma Reports First Quarter 2025 Results and Business Highlights

THOMSON REUTERS

Traws Pharma Reports Full Year 2024 Results and Business Highlights

THOMSON REUTERS

Traws Pharma Inc - Cash Runway to Support Operations Into Q1 2026

THOMSON REUTERS

Press Release: Traws Pharma Reports Full Year 2024 Results and Business Highlights

Traws Pharma CEO Werner Cautreels Retires, Chair Iain Duke Succeeds on Interim Basis

MT Newswires Live

Traws Pharma CEO Werner Cautreels retires, Iain Dukes named interim CEO

Traws Pharma Inc - Werner Cautreels to Retire as CEO, Remain as Board Member

THOMSON REUTERS

Traws Pharma Inc - Iain Dukes to Become Interim CEO

THOMSON REUTERS

Traws Pharma Announces Management Updates

Traws Pharma to Host Investor Event on Bird Flu and COVID Product Candidates Virtual Event to be Held on Monday, March 31, 2025 at 10:00 AM ET

Traws Pharma’s COVID-19 Candidate, Ratutrelvir, Presented at ICAR

Traws Pharma Inc - FDA Briefing Documents in Preparation for Discussion of Potential Accelerated Path to Approval

THOMSON REUTERS

Traws Pharma Antiviral Bird Flu Program, Tivoxavir Marboxil, Shows Positive Data in Non-Human Primates

THOMSON REUTERS

Traws Pharma Antiviral Bird Flu Program, Tivoxavir Marboxil, Shows Positive Data in Non-human Primates

BRIEF-Traws Pharma Presents Positive Data For TXM As Bird Flu Treatment At ICAR

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/TRAW/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"TRAW","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"TRAW\",,,,,undefined,":{"symbol":"TRAW","market":"US","secType":"STK","nameCN":"TRAWS PHARMA","latestPrice":1.65,"timestamp":1749240000000,"preClose":1.48,"halted":0,"volume":493125,"hourTrading":{"tag":"盘后","latestPrice":1.67,"preClose":1.65,"latestTime":"19:59 EDT","volume":7086,"amount":11670.9305,"timestamp":1749254344910},"delay":0,"floatShares":4196300,"shares":5564315,"eps":-35.21255,"marketStatus":"Market Closed","change":0.17,"latestTime":"06-06 16:00:00 EDT","open":1.46,"high":1.73,"low":1.45,"amount":807063.1687500001,"amplitude":0.189189,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":0,"etf":0,"ttmEps":-35.21255,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1749456000000},"marketStatusCode":7,"adr":0,"listingDate":1374724800000,"exchange":"NASDAQ","adjPreClose":1.48,"preHourTrading":{"tag":"盘前","latestPrice":1.45,"preClose":1.48,"latestTime":"09:27 EDT","volume":13495,"amount":19647.300326,"timestamp":1749216422280},"postHourTrading":{"tag":"盘后","latestPrice":1.67,"preClose":1.65,"latestTime":"19:59 EDT","volume":7086,"amount":11670.9305,"timestamp":1749254344910},"volumeRatio":0.037650348827545393,"impliedVol":1.7917,"impliedVolPercentile":0.9865},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"TRAW\",,,,,undefined,":{"symbol":"TRAW","floatShares":4196300,"roa":"-83.59%","roe":"-2331.25%","lyrEps":-35.212551,"volumeRatio":0.037650348827545393,"shares":5564315,"dividePrice":0,"high":1.73,"amplitude":0.189189,"preClose":1.48,"low":1.45,"week52Low":0.97,"pbRate":"1.53","psRate":"40.45","week52High":19.44,"institutionHeld":0,"latestPrice":1.65,"eps":-35.21255,"divideRate":0,"volume":493125,"delay":0,"ttmEps":-35.21255,"open":1.46,"prevYearClose":8.88,"prevWeekClose":1.42,"prevMonthClose":1.42,"prevQuarterClose":2.3,"fiveDayClose":1.42,"twentyDayClose":1.4,"sixtyDayClose":2.72},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"TRAW\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2538562469","title":"BRIEF-Traws Pharma Announces Receipt Of FDA Guidance On Tivoxavir Marboxil, Plans For Pursuing Stockpiling For Pandemic Preparedness","url":"https://stock-news.laohu8.com/highlight/detail?id=2538562469","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2538562469?lang=en_us&edition=fundamental","pubTime":"2025-05-27 20:43","pubTimestamp":1748349801,"startTime":"0","endTime":"0","summary":"BRIEF-Traws Pharma Announces Receipt Of FDA Guidance On Tivoxavir Marboxil, Plans For Pursuing Stockpiling For Pandemic PreparednessMay 27 (Reuters) - Traws Pharma Inc TRAW.O:TRAWS PHARMA ANNOUNCES RE","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250527:nFWN3RZ1GW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","TRAW"],"gpt_icon":0},{"id":"2538446572","title":"Traws Pharma Announces Receipt of FDA Guidance on Tivoxavir Marboxil and Reports Plans for Pursuing Stockpiling for Pandemic Preparedness","url":"https://stock-news.laohu8.com/highlight/detail?id=2538446572","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2538446572?lang=en_us&edition=fundamental","pubTime":"2025-05-27 20:02","pubTimestamp":1748347358,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250527:nFWN3RZ1GW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","TRAW"],"gpt_icon":0},{"id":"2535841620","title":"BRIEF-Traws Pharma Reports First Quarter 2025 Results And Business Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2535841620","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535841620?lang=en_us&edition=fundamental","pubTime":"2025-05-15 19:40","pubTimestamp":1747309208,"startTime":"0","endTime":"0","summary":"BRIEF-Traws Pharma Reports First Quarter 2025 Results And Business HighlightsTraws Pharma Inc TRAW.O:TRAWS PHARMA REPORTS FIRST QUARTER 2025 RESULTS AND BUSINESS HIGHLIGHTSSource text: ID:nGNX3SXCyTFurther company coverage: TRAW.O","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250515:nTUA1YNPXW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TRAW","BK4007"],"gpt_icon":0},{"id":"2535846359","title":"Traws Pharma Q1 EPS $2.09 Beats $(8.04) Estimate, Sales $57.00K Miss $60.00K Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2535846359","media":"Benzinga","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535846359?lang=en_us&edition=fundamental","pubTime":"2025-05-15 19:12","pubTimestamp":1747307555,"startTime":"0","endTime":"0","summary":"Traws Pharma (NASDAQ:TRAW) reported quarterly earnings of $2.09 per share which beat the analyst consensus estimate of $(8.04) by 126 percent. This is a 135.3 percent increase over losses of $(5.92) per share from the","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/05/45432633/traws-pharma-q1-eps-2-09-beats-8-04-estimate-sales-57-00k-miss-60-00k-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TRAW"],"gpt_icon":0},{"id":"2535845952","title":"Traws Pharma Inc. Reports Q1 2025 Results: Revenue Steady at $57K, Net Income Soars to $21.5M, EPS at $2.17","url":"https://stock-news.laohu8.com/highlight/detail?id=2535845952","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535845952?lang=en_us&edition=fundamental","pubTime":"2025-05-15 19:02","pubTimestamp":1747306971,"startTime":"0","endTime":"0","summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Traws Pharma Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on May 15, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250515:nNDL7G7GyY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TRAW"],"gpt_icon":0},{"id":"2535845593","title":"Traws Pharma Reports First Quarter 2025 Results and Business Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2535845593","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535845593?lang=en_us&edition=fundamental","pubTime":"2025-05-15 19:00","pubTimestamp":1747306803,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250515:nTUA1YNPXW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["TRAW","BK4007"],"gpt_icon":0},{"id":"2523941147","title":"Traws Pharma Reports Full Year 2024 Results and Business Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2523941147","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523941147?lang=en_us&edition=fundamental","pubTime":"2025-03-31 21:00","pubTimestamp":1743426002,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250331:nTUA8TTYWM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","TRAW"],"gpt_icon":0},{"id":"2523294177","title":"Traws Pharma Inc - Cash Runway to Support Operations Into Q1 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2523294177","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523294177?lang=en_us&edition=fundamental","pubTime":"2025-03-31 21:00","pubTimestamp":1743426002,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250331:nTUA8TTYWM:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["TRAW","BK4007"],"gpt_icon":0},{"id":"2523941200","title":"Press Release: Traws Pharma Reports Full Year 2024 Results and Business Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2523941200","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523941200?lang=en_us&edition=fundamental","pubTime":"2025-03-31 21:00","pubTimestamp":1743426000,"startTime":"0","endTime":"0","summary":"Tivoxavir marboxil's potential as a single dose therapeutic agent for bird flu supported by significant antiviral activity in three well accepted animal models and positive Phase 1 data. Ongoing FDA interaction to align on path forward for tivoxavir marboxil, including potential for accelerated approval utilizing the \"Animal Rule\". Cash Runway to support planned operations into Q1 2026. Investor Update call today, March 31, 2025 at 10:00 AM ET. NEWTOWN, Pa., March 31, 2025  -- Traws Pharma, Inc.  , a clinical-stage biopharmaceutical company developing novel therapies to target critical threats to human health from respiratory viral diseases, today reported financial results for the year ended December 31, 2024 and provided recent business highlights, with updates to the Company's investigational programs including lead product candidate, tivoxavir marboxil  in development for bird flu, and ratutrelvir in development for COVID.-- Bird flu: Finalize formulation and CMC scale up","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BNTX","BK4551","BK4535","BK4585","BK4568","BK4181","CEO","TRAW","PK","BK4588","BK4548","BK4218","BK4007","BK4139"],"gpt_icon":0},{"id":"2523541635","title":"Traws Pharma CEO Werner Cautreels Retires, Chair Iain Duke Succeeds on Interim Basis","url":"https://stock-news.laohu8.com/highlight/detail?id=2523541635","media":"MT Newswires Live","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523541635?lang=en_us&edition=fundamental","pubTime":"2025-03-29 04:58","pubTimestamp":1743195525,"startTime":"0","endTime":"0","summary":"Traws Pharma  late Friday said Werner Cautreels will retire as chief executive officer after the biopharmaceutical company completes and files its 2024 annual report, expected by Monday.Cautreels will be succeeded on an interim basis by Iain D. Dukes, Traws board chair. Dukes will continue as board chair.Cautreels also will remain a member of the Traws board and work as a special adviser at the company over the next 12 months, it said.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4007","TRAW"],"gpt_icon":0},{"id":"2523989633","title":"Traws Pharma CEO Werner Cautreels retires, Iain Dukes named interim CEO","url":"https://stock-news.laohu8.com/highlight/detail?id=2523989633","media":"TIPRANKS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523989633?lang=en_us&edition=fundamental","pubTime":"2025-03-29 04:35","pubTimestamp":1743194129,"startTime":"0","endTime":"0","summary":"Traws Pharma (TRAW) announced the retirement of Werner Cautreels, CEO, effective on or about close of business on March 31 after the company files ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/traws-pharma-ceo-werner-cautreels-retires-iain-dukes-named-interim-ceo?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/traws-pharma-ceo-werner-cautreels-retires-iain-dukes-named-interim-ceo?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","TRAW"],"gpt_icon":0},{"id":"2523638414","title":"Traws Pharma Inc - Werner Cautreels to Retire as CEO, Remain as Board Member","url":"https://stock-news.laohu8.com/highlight/detail?id=2523638414","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523638414?lang=en_us&edition=fundamental","pubTime":"2025-03-29 04:30","pubTimestamp":1743193805,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250328:nFWN3QB1EU:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","TRAW","BK4139","BK4539","IKNA","IOVA"],"gpt_icon":0},{"id":"2523384286","title":"Traws Pharma Inc - Iain Dukes to Become Interim CEO","url":"https://stock-news.laohu8.com/highlight/detail?id=2523384286","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523384286?lang=en_us&edition=fundamental","pubTime":"2025-03-29 04:30","pubTimestamp":1743193805,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250328:nFWN3QB1EU:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IKNA","BK4007","IOVA","BK4539","TRAW","BK4139"],"gpt_icon":0},{"id":"2523633532","title":"Traws Pharma Announces Management Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2523633532","media":"GlobeNewswire","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523633532?lang=en_us&edition=fundamental","pubTime":"2025-03-29 04:30","pubTimestamp":1743193800,"startTime":"0","endTime":"0","summary":"Werner Cautreels, PhD, to retire as CEO, while continuing as a Board Member. Iain D. Dukes, D Phil, Executive Board Chairman, to become Interim CEO. NEWTOWN, Pa., March 28, 2025  -- Traws Pharma, Inc.  , a clinical-stage biopharmaceutical company developing novel therapies to target critical threats to human health from respiratory viral diseases, today announced the retirement of Werner Cautreels, PhD, Chief Executive Officer , effective on or about close of business on March 31, 2025 after the Company files its Annual Report on Form 10-K with the Securities and Exchange Commission. Iain D. Dukes, D Phil, will assume the role of Interim CEO. In addition to his new responsibilities, Dr. Dukes will continue to serve as Traws’ Chairman.Dr. Dukes has held leadership roles in public and private biopharmaceutical companies, leveraging vast experience in corporate, strategic and product development. Dr. Cautreels will continue in his role as a member of the Traws Board of Directors and trans","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/traws-pharma-announces-management-updates-203000831.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IKNA","BK4007","IOVA","TRAW","CEO","BK4139"],"gpt_icon":1},{"id":"2522769548","title":"Traws Pharma to Host Investor Event on Bird Flu and COVID Product Candidates  Virtual Event to be Held on Monday, March 31, 2025 at 10:00 AM ET","url":"https://stock-news.laohu8.com/highlight/detail?id=2522769548","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522769548?lang=en_us&edition=fundamental","pubTime":"2025-03-26 19:30","pubTimestamp":1742988600,"startTime":"0","endTime":"0","summary":"Event to highlight the differentiated features of Traws oral small molecule product candidates: Tivoxavir Marboxil, a single dose, CAP-dependent endonuclease inhibitor for Bird FluRatutrelvir, a main ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/03/26/3049529/0/en/Traws-Pharma-to-Host-Investor-Event-on-Bird-Flu-and-COVID-Product-Candidates-Virtual-Event-to-be-Held-on-Monday-March-31-2025-at-10-00-AM-ET.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4548","HST","AM","BK4585","BK4181","BK4535","TRAW","BK4144","BK4590","BK4561","BK4581","CDC","BK4568","BK4551","BK4218","BK4588","BK4139","PK","BK4007","BNTX","ET"],"gpt_icon":0},{"id":"2522075303","title":"Traws Pharma’s COVID-19 Candidate, Ratutrelvir, Presented at ICAR","url":"https://stock-news.laohu8.com/highlight/detail?id=2522075303","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522075303?lang=en_us&edition=fundamental","pubTime":"2025-03-25 19:30","pubTimestamp":1742902200,"startTime":"0","endTime":"0","summary":"Preclinical and Phase 1 data suggest that ratutrelvir can be used without ritonavir and may reduce the likelihood of COVID rebound and the risk of long COVID due to a longer treatment regimen. Preparations are underway for FDA interactions and initiation of Phase 2 studies. “We believe ratutrelvir has the potential to be a highly differentiated, broadly active treatment for COVID. Preparations are underway to meet with the FDA to align on a path forward and initiate Phase 2 studies,” noted Werner Cautreels, PhD, Chief Executive Officer for Traws Pharma. “We plan to host an Investor Event on Mo","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/traws-pharma-covid-19-candidate-113000124.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4218","TRAW","BK4139","BK4181","CDC","BK4535","PK","BK4568","BK4585","BNTX","BK4588","BK4007","BK4548","BK4551"],"gpt_icon":0},{"id":"2521746828","title":"Traws Pharma Inc - FDA Briefing Documents in Preparation for Discussion of Potential Accelerated Path to Approval","url":"https://stock-news.laohu8.com/highlight/detail?id=2521746828","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521746828?lang=en_us&edition=fundamental","pubTime":"2025-03-24 19:01","pubTimestamp":1742814116,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250324:nFWN3Q715T:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["TRAW","BK4007"],"gpt_icon":0},{"id":"2521450367","title":"Traws Pharma Antiviral Bird Flu Program, Tivoxavir Marboxil, Shows Positive Data in Non-Human Primates","url":"https://stock-news.laohu8.com/highlight/detail?id=2521450367","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521450367?lang=en_us&edition=fundamental","pubTime":"2025-03-24 19:01","pubTimestamp":1742814116,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250324:nFWN3Q715T:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","TRAW"],"gpt_icon":0},{"id":"2521746248","title":"Traws Pharma Antiviral Bird Flu Program, Tivoxavir Marboxil, Shows Positive Data in Non-human Primates","url":"https://stock-news.laohu8.com/highlight/detail?id=2521746248","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521746248?lang=en_us&edition=fundamental","pubTime":"2025-03-24 19:00","pubTimestamp":1742814000,"startTime":"0","endTime":"0","summary":"Tivoxavir marboxil (TXM), administered as a single dose in non-human primates, significantly reduced lung viremia and prevented weight loss, two key measures of antiviral activity in preclinical bird ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/03/24/3047706/0/en/Traws-Pharma-Antiviral-Bird-Flu-Program-Tivoxavir-Marboxil-Shows-Positive-Data-in-Non-human-Primates.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","CDC","TRAW"],"gpt_icon":0},{"id":"2521404409","title":"BRIEF-Traws Pharma Presents Positive Data For TXM As Bird Flu Treatment At ICAR","url":"https://stock-news.laohu8.com/highlight/detail?id=2521404409","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521404409?lang=en_us&edition=fundamental","pubTime":"2025-03-21 19:03","pubTimestamp":1742554987,"startTime":"0","endTime":"0","summary":"BRIEF-Traws Pharma Presents Positive Data For TXM As Bird Flu Treatment At ICARMarch 21 (Reuters) - Traws Pharma Inc TRAW.O:TRAWS PHARMA INC - PRESENTS POSITIVE DATA FOR TXM AS BIRD FLU TREATMENT AT ICARSource text: ID:nGNX96RXJBFurther company coverage: TRAW.O ((Reuters.Briefs@thomsonreuters.com))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250321:nFWN3Q4022:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TRAW","BK4007"],"gpt_icon":0}],"pageSize":20,"totalPage":4,"pageCount":1,"totalSize":62,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/TRAW\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-05-15","symbol":"TRAW","fiscalQuarterEnding":"2025/03","expectedEps":null,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1747281600000,"reportTimeType":"pre","actualEps":2.09},{"market":"US","date":"2025-03-31","symbol":"TRAW","fiscalQuarterEnding":"2024/12","expectedEps":null,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1743393600000,"reportTimeType":"pre","actualEps":95.66},{"market":"US","date":"2024-11-14","symbol":"TRAW","fiscalQuarterEnding":"2024/09","expectedEps":-6.25,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1731560400000,"reportTimeType":"post","actualEps":-8.81},{"market":"US","date":"2024-09-23","symbol":"TRAW","defaultRemindTime":1727098200000,"type":"split","dateTimestamp":1727064000000,"forFactor":25,"toFactor":1,"ratio":25},{"market":"US","date":"2024-08-15","symbol":"TRAW","fiscalQuarterEnding":"2024/06","expectedEps":null,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1723694400000,"reportTimeType":"pre","actualEps":-4.87}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"TRAW\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"TRAW\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/TRAW\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"TRAW","date":"2025-06-06","current":-0.058802,"percent":0.858182,"low":-0.930105,"twenty":-0.622492,"median":-0.108696,"eighty":-0.062794,"high":-0.033516,"avg":-0.256868,"sd":0.278763,"marketCap":8235186},"quantilePoints":[{"date":"2024-04-05","current":-0.930105,"twenty":-0.930105,"median":-0.930105,"eighty":-0.930105,"marketCap":17623624},{"date":"2024-04-12","current":-0.875242,"twenty":-0.899279,"median":-0.879971,"eighty":-0.87246,"marketCap":16584087},{"date":"2024-04-19","current":-0.774197,"twenty":-0.884701,"median":-0.859217,"eighty":-0.774642,"marketCap":14669484},{"date":"2024-04-26","current":-0.703922,"twenty":-0.875242,"median":-0.784323,"eighty":-0.745597,"marketCap":13337908},{"date":"2024-05-03","current":-0.713993,"twenty":-0.87246,"median":-0.75973,"eighty":-0.713993,"marketCap":13528735},{"date":"2024-05-10","current":-0.722239,"twenty":-0.859217,"median":-0.743093,"eighty":-0.71377,"marketCap":13684982},{"date":"2024-05-17","current":-0.7463,"twenty":-0.799236,"median":-0.738475,"eighty":-0.713993,"marketCap":13549821},{"date":"2024-05-24","current":-0.73457,"twenty":-0.794005,"median":-0.741761,"eighty":-0.718444,"marketCap":13336853},{"date":"2024-05-31","current":-0.675921,"twenty":-0.778515,"median":-0.736522,"eighty":-0.713681,"marketCap":12272014},{"date":"2024-06-07","current":-0.836261,"twenty":-0.794624,"median":-0.73457,"eighty":-0.711322,"marketCap":15183160},{"date":"2024-06-14","current":-0.873049,"twenty":-0.83888,"median":-0.740589,"eighty":-0.71288,"marketCap":15851082},{"date":"2024-06-21","current":-0.649387,"twenty":-0.836845,"median":-0.738475,"eighty":-0.709541,"marketCap":11790270},{"date":"2024-06-28","current":-0.62709,"twenty":-0.83835,"median":-0.738475,"eighty":-0.706993,"marketCap":11385454},{"date":"2024-07-05","current":-0.557395,"twenty":-0.836651,"median":-0.734469,"eighty":-0.698614,"marketCap":10120072},{"date":"2024-07-12","current":-0.483661,"twenty":-0.814046,"median":-0.728873,"eighty":-0.672205,"marketCap":8781358},{"date":"2024-07-15","current":-0.554747,"twenty":-0.806641,"median":-0.726171,"eighty":-0.663181,"marketCap":10071990},{"date":"2024-08-02","current":-0.532446,"twenty":-0.799236,"median":-0.724978,"eighty":-0.649387,"marketCap":9667086},{"date":"2024-08-09","current":-0.491259,"twenty":-0.797102,"median":-0.722239,"eighty":-0.600613,"marketCap":8919304},{"date":"2024-08-16","current":-0.066488,"twenty":-0.794005,"median":-0.718444,"eighty":-0.532446,"marketCap":9112137},{"date":"2024-08-23","current":-0.065565,"twenty":-0.774642,"median":-0.71377,"eighty":-0.508851,"marketCap":8985580},{"date":"2024-08-30","current":-0.06743,"twenty":-0.774197,"median":-0.709986,"eighty":-0.494812,"marketCap":9241226},{"date":"2024-09-06","current":-0.06538,"twenty":-0.762623,"median":-0.702951,"eighty":-0.490604,"marketCap":8960268},{"date":"2024-09-13","current":-0.062794,"twenty":-0.758648,"median":-0.694503,"eighty":-0.071087,"marketCap":8605907},{"date":"2024-09-20","current":-0.057254,"twenty":-0.751084,"median":-0.683063,"eighty":-0.068232,"marketCap":7846562},{"date":"2024-09-27","current":-0.081301,"twenty":-0.74722,"median":-0.649387,"eighty":-0.067774,"marketCap":11142278},{"date":"2024-10-04","current":-0.073971,"twenty":-0.746382,"median":-0.624791,"eighty":-0.068232,"marketCap":10137646},{"date":"2024-10-11","current":-0.065174,"twenty":-0.745738,"median":-0.557395,"eighty":-0.067596,"marketCap":8932088},{"date":"2024-10-18","current":-0.062642,"twenty":-0.744673,"median":-0.543597,"eighty":-0.067316,"marketCap":8585034},{"date":"2024-10-25","current":-0.111702,"twenty":-0.743234,"median":-0.515682,"eighty":-0.066488,"marketCap":15308680},{"date":"2024-10-31","current":-0.109715,"twenty":-0.741526,"median":-0.508851,"eighty":-0.066652,"marketCap":15036392},{"date":"2024-11-08","current":-0.111592,"twenty":-0.739321,"median":-0.498158,"eighty":-0.06682,"marketCap":15293553},{"date":"2024-11-15","current":-0.123204,"twenty":-0.736132,"median":-0.492107,"eighty":-0.067201,"marketCap":16884930},{"date":"2024-11-22","current":-0.096923,"twenty":-0.734509,"median":-0.489621,"eighty":-0.06743,"marketCap":13645248},{"date":"2024-11-29","current":-0.098427,"twenty":-0.734469,"median":-0.48099,"eighty":-0.067496,"marketCap":13857037},{"date":"2024-12-06","current":-0.108407,"twenty":-0.733312,"median":-0.130241,"eighty":-0.067596,"marketCap":15262104},{"date":"2024-12-13","current":-0.104014,"twenty":-0.729414,"median":-0.121316,"eighty":-0.067685,"marketCap":14643681},{"date":"2024-12-20","current":-0.114642,"twenty":-0.725217,"median":-0.114642,"eighty":-0.068025,"marketCap":16139817},{"date":"2024-12-27","current":-0.244993,"twenty":-0.723719,"median":-0.117501,"eighty":-0.068353,"marketCap":34491315},{"date":"2025-01-03","current":-0.186323,"twenty":-0.723452,"median":-0.123204,"eighty":-0.068427,"marketCap":26231553},{"date":"2025-01-10","current":-0.173429,"twenty":-0.722482,"median":-0.130241,"eighty":-0.069344,"marketCap":24416220},{"date":"2025-01-17","current":-0.146996,"twenty":-0.721141,"median":-0.147157,"eighty":-0.069786,"marketCap":20694789},{"date":"2025-01-24","current":-0.13797,"twenty":-0.719413,"median":-0.140763,"eighty":-0.070056,"marketCap":19424056},{"date":"2025-01-31","current":-0.156666,"twenty":-0.718444,"median":-0.146996,"eighty":-0.070643,"marketCap":22056288},{"date":"2025-02-07","current":-0.178157,"twenty":-0.715773,"median":-0.153981,"eighty":-0.07105,"marketCap":25081842},{"date":"2025-02-14","current":-0.173739,"twenty":-0.713859,"median":-0.157526,"eighty":-0.072709,"marketCap":24459897},{"date":"2025-02-21","current":-0.121618,"twenty":-0.713592,"median":-0.156666,"eighty":-0.073848,"marketCap":17121928},{"date":"2025-02-28","current":-0.087129,"twenty":-0.71288,"median":-0.149414,"eighty":-0.074131,"marketCap":12266456},{"date":"2025-03-07","current":-0.070533,"twenty":-0.710432,"median":-0.144632,"eighty":-0.071013,"marketCap":9929988},{"date":"2025-03-14","current":-0.07157,"twenty":-0.706225,"median":-0.135069,"eighty":-0.071013,"marketCap":10076017},{"date":"2025-03-21","current":-0.074682,"twenty":-0.703145,"median":-0.130241,"eighty":-0.070984,"marketCap":10514105},{"date":"2025-03-28","current":-0.066643,"twenty":-0.70173,"median":-0.123448,"eighty":-0.070533,"marketCap":9382378},{"date":"2025-04-04","current":-0.066422,"twenty":-0.698614,"median":-0.121618,"eighty":-0.069679,"marketCap":11060862},{"date":"2025-04-11","current":-0.053321,"twenty":-0.692996,"median":-0.117957,"eighty":-0.068372,"marketCap":8879132},{"date":"2025-04-17","current":-0.060633,"twenty":-0.690629,"median":-0.115407,"eighty":-0.067596,"marketCap":10096842},{"date":"2025-04-25","current":-0.046618,"twenty":-0.687348,"median":-0.111751,"eighty":-0.066971,"marketCap":7762898},{"date":"2025-05-02","current":-0.042961,"twenty":-0.674063,"median":-0.111618,"eighty":-0.066488,"marketCap":7154043},{"date":"2025-05-09","current":-0.042657,"twenty":-0.663181,"median":-0.111481,"eighty":-0.065417,"marketCap":7103306},{"date":"2025-05-16","current":-0.033516,"twenty":-0.647743,"median":-0.11053,"eighty":-0.064788,"marketCap":5581169},{"date":"2025-05-23","current":-0.045648,"twenty":-0.63835,"median":-0.110157,"eighty":-0.064588,"marketCap":6392975},{"date":"2025-05-30","current":-0.055226,"twenty":-0.62709,"median":-0.109384,"eighty":-0.063348,"marketCap":7734397},{"date":"2025-06-06","current":-0.058802,"twenty":-0.622492,"median":-0.108696,"eighty":-0.062794,"marketCap":8235186}],"updateTime":1749327481770}}}